Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

Francesco Caiazza, Patricia M. McGowan, Maeve Mullooly, Alan Murray, Naoise C. Synnott, Norma O’Donovan, L. Flanagan, Christopher J. Tape, Gillian Murphy, J. Crown, M. J. DuffyBritish 2025 · DOI · OpenAlex

Introduction

This article serves as a formal correction to a 2015 study investigating the role of ADAM-17 (A Disintegrin and Metalloproteinase 17) in triple-negative breast cancer (TNBC). ADAM-17 is a key enzyme responsible for shedding cell-surface proteins, such as growth factors, that drive tumor progression. Given that TNBC lacks standard therapeutic targets (ER, PR, and HER2), inhibiting ADAM-17 presents a promising alternative strategy.

The Nature of the Correction

The authors have updated Figure 4 to address errors in the presentation of representative images for 3D cell culture experiments. Specifically, Panels A and B have been replaced with new images at 4x magnification. These updated visuals are sourced from separate wells in replicate experiments, providing a more accurate and transparent representation of the consistent anti-tumour effects observed across trials.

Methodology and 3D Modeling

To evaluate the efficacy of the inhibitory monoclonal antibody D1(A12), the researchers utilized two distinct 3D culture models:

  1. Alvetex Scaffolds: A porous polystyrene membrane that mimics the 3D architecture of the extracellular matrix.
  2. Matrigel "On-Top" Assay: A basement membrane extract used to observe complex cellular structure formation.

The study focused on two TNBC cell lines, HCC1143 and HCC1937. Cell viability and growth were quantified using neutral red staining, which serves as a proxy for the ability of the cells to colonize the 3D environments.

Key Results and Conclusions

The correction confirms that the original scientific conclusions remain robust. Treatment with 200 nM of the D1(A12) antibody significantly suppressed the growth and colonization of TNBC cells in both 3D models compared to the IgG control.

  • Statistical Significance: The inhibitory effects remained statistically significant ($P < 0.05$ and $P < 0.001$) based on the mean of three independent experiments.
  • Visual Evidence: The corrected images provide clear visual confirmation of reduced cell density and scaffold coverage in treated groups.

Impact on the Field

While this correction addresses visual data presentation, it reinforces the validity of targeting ADAM-17 in aggressive breast cancers. The use of 3D culture models provides a more physiologically relevant context than traditional 2D cultures, bridging the gap toward potential in vivo and clinical applications. This update ensures the integrity of the published record and supports the continued investigation of D1(A12) as a therapeutic candidate for TNBC.

Summary updated

BibTeX
@inproceedings{caiazza2025correction,
  author = {Francesco Caiazza and Patricia M. McGowan and Maeve Mullooly and Alan Murray and Naoise C. Synnott and Norma O’Donovan and L. Flanagan and Christopher J. Tape and Gillian Murphy and J. Crown and M. J. Duffy and Christopher Tape},
  title = {{Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells}},
  booktitle = {British},
  year = {2025},
  doi = {10.1038/s41416-025-02973-y},
}
Figure